Molecular pathologic testing plays an important role for the diagnosis, prognostication and decision of treatment in lymphoproliferative disease. Classification of malignant lymphomas has been evolved to define unique clinicopathological entities for optimizing management of patients and thereby improving the clinical outcome. Advances in radiological and diagnostic techniques in medicine have made it possible to detect diseases earlier and with smaller sized tissues. Thus, pathologists are facing challenges in the diagnosis of lymphoproliferative disease. In addition, gene expression profile has clinical implication for the prognosis and patient management as exampled by diffuse large B-cell lymphoma (DLBCL). Moreover, various molecular genetic alterations have been reported in lymphoma, which are likely candidates for target therapy in the era of precision medicine. Therefore, pathologic diagnosis of malignant lymphoma currently demands multimodal approach including morphology, immunophenotype, viral status, and genetic alterations. In addition, introduction of next-generation sequencing (NGS) techniques to the pathologic diagnosis of lymphoma is around the corner. This review is intended to give a brief overview and guideline for molecular tests for lymphoproliferative disease with a focus on malignant lymphoma, including the B- and T-cell clonality test, molecular cytogenetic test, determination of cell-of-origin (COO) in DLBCL, and molecular genetic tests incorporated in the 2016 revision of World Health Organization (WHO) classification of lymphoid neoplasm. A perspective on NGS tests in lymphoma will also be addressed.

B- AND T-CELL CLONALITY TEST
============================

Background: Ig and T-cell receptor gene rearrangements
------------------------------------------------------

B and T cells are the only cells undergoing physiological gene rearrangement of their genomic DNA to produce unique Ig and T-cell receptor (TCR) molecules, respectively. The Ig and TCR genes contain many different variable (V), diversity (D), and joining (J) gene segments, which undergoes random gene rearrangement during early lymphoid development \[[@b1-jptm-2017-04-09],[@b2-jptm-2017-04-09]\]. Ig heavy chain (*IGH*), TCR beta (*TCRB*), and TCR delta (*TCRD*) genes have V, D, and J gene segments, and Ig kappa (*IGK*), Ig lambda (*IGL*), TCR alpha (*TCRA*), and TCR gamma (*TCRG*) genes have V and J gene segments \[[@b3-jptm-2017-04-09]\]. To further create diversity of Ig and TCR molecules, variable numbers of nucleotides are lost and inserted at the joining lesion (i.e., the V-D, V-J, or D-J junction) through the action of terminal deoxynucleotidyl transferase (TdT) \[[@b4-jptm-2017-04-09]\]. Consequently, these processes produce an incredibly large repertoire of Ig and TCR molecules due to both the combinatorial diversity and the junctional diversity \[[@b5-jptm-2017-04-09]\]. The normal blood B-cell receptor (BCR) and TCR repertoire is estimated to comprise more than 1012 distinct sequences, and many of these are present at low frequency under physiologic condition \[[@b5-jptm-2017-04-09]\]. Thus, the detection of a single predominant BCR or TCR population indicates the presence of a clonally expanded B- or T-cell population, respectively.

Ig and TCR gene rearrangements occur in a hierarchical order. During B-cell development, the *IGH* genes are first rearranged, followed by rearrangement of *IGK* genes potentially resulting in IgH/κ expression. Alternatively, *IGH* gene rearrangement is followed by *IGK* deletion and IGL rearrangement, potentially resulting in IgH/κ expression \[[@b5-jptm-2017-04-09]\]. Thus, *IGH* gene is most widely utilized in the clonality test for B-cell proliferative disease, followed by *IGK* and *IGL* \[[@b3-jptm-2017-04-09],[@b6-jptm-2017-04-09]\]. During T-cell development, *TCRD* gene rearrangement occurs first in early thymocytes, followed by *TCRG* gene rearrangement, potentially resulting in TCRγδ expression in a small subset of thymocytes and differentiation to γδT cells. However, in most thymocytes, *TCRG* and *TCRD* rearrangements are followed by *TCRB* rearrangement and subsequent *TCRA* rearrangement (this rearrangement leads to the deletion of the *TCRD* locus because *TCRD* gene is located within the *TCRA* gene), potentially followed by TCRαβ expression and further differentiation into αβT cells. Consistent with this hierarchical gene rearrangement, virtually all αβT cells have rearranged *TCRG* as well as *TCRB* and *TCRA* genes; however, the γδT cells harbor rearranged *TCRG* and only rarely contain rearranged *TCRB* genes \[[@b3-jptm-2017-04-09],[@b7-jptm-2017-04-09],[@b8-jptm-2017-04-09]\]. This has important implications for T-cell clonality testing, because virtually all the αβTCR expressing T-cell lymphomas as well as the γδT cell neoplasms will have a rearranged *TCRG* gene. Thus, *TCRG* gene is most widely utilized, followed by *TCRB* and then *TCRA*, for T-cell clonality test \[[@b3-jptm-2017-04-09],[@b6-jptm-2017-04-09],[@b8-jptm-2017-04-09]\].

Indication
----------

Molecular clonality test is required for making a final diagnosis of lymphoproliferative disorder when the diagnosis is inconclusive despite of extensive morphologic and immunophenotypic analysis. Common indications are as follows: (1) all suspected T-cell proliferations, (2) any suspected B-cell proliferation when morphology and immunophenotyping are not conclusive, (3) when limited tissues are available (such as skin biopsy and needle biopsy), (4) to determine involvement of lymphoma in cytology material, especially in limited specimen such as cerebrospinal fluid and vitreous fluid, (5) to detect minimal residual disease, (6) when lymphoproliferations are noted in immunodeficient patients, including post-transplant patients, (7) to evaluate the clonal relationship between two lymphoid malignancies in one patient or to differentiate a relapse from a second malignancy, (8) to further classify malignancy via Ig/TCR gene rearrangement patterns or particular chromosome aberrations, and (9) to stage lymphomas, occasionally \[[@b3-jptm-2017-04-09]\].

Methodology
-----------

B- and T-cell clonality can be either indirectly determined by detection of monotypic Ig and TCR molecules or directly by genetic tests. Because reactive polyclonal B cells have Igκ/Igλ ratio ranging from 0.7 to 2.8, Ig light chain expression with Igκ/Igλ ratios of \> 4.0 or \< 0.5 has been considered as an evidence suggestive of clonal B-cell proliferation. Ig light chain restriction can be detected by flow cytometry, *in situ* hybridization or immunohistochemistry \[[@b9-jptm-2017-04-09]\]. The detection of monotypic TCR expression can be done using flow cytometry for TCR molecules. However, these indirect methods have limitations because flow cytometry is difficult to perform using tissue samples, antibodies against specific TCR molecules are limited and usage of TCR repertoire is often restricted even under non-neoplastic condition. In contrast, molecular techniques, including southern blot and polymerase chain reaction (PCR) analyses, are broadly applicable to the detection of clonally rearranged Ig and TCR genes.

Southern blot analysis has long been considered as a gold standard for molecular clonality studies. It detects rearranged DNA fragments after digestion with restriction enzymes. Large amount (10--20 mg) of high quality DNA from fresh tissue, well-chosen restriction enzymes, well-designed DNA probes and technical excellence are required for Southern blot analysis. In addition, because Southern blot analysis basically focuses on the combinational diversity of Ig and TCR gene segments, it is useful for the assessment of *IGH*, *IGK*, and *TCRB* genes, but is of limited value for highly complex *IGL* and *TCRA* genes or relatively simple *TCRG* and *TCRD* genes \[[@b3-jptm-2017-04-09],[@b8-jptm-2017-04-09]\]. Thus, despite the high reliability of Southern blot, it has been replaced by PCR techniques in clinical laboratories.

PCR techniques to detect rearranged Ig and TCR genes have considerable merits; it can be performed using a small amount of DNA and a variety of clinical samples including formalin fixed paraffin-embedded (FFPE) tissue, fresh tissue, and cytology samples, the turnaround time is short, and the PCR-based assay is relatively easy to perform and standardize. In PCR-based clonality test, as mentioned above, *IGH* genes are most widely used for B-cell clonality test followed by *IGK*, and *TCRG* genes are most widely utilized for T-cell clonality test followed by *TCRB*. PCR-based clonality test basically adopts multiplex-PCR techniques using multiple primers complementary to consensus or framework sequence of Ig and TCR gene families/segments. Due to the junctional diversity during gene rearrangement, polyclonal B and T cells produce PCR products having variable size and nucleotide composition. However, monoclonal B and T cells produce PCR products having identical size and nucleotide composition, which can be detected as an evidence of monoclonality \[[@b3-jptm-2017-04-09],[@b8-jptm-2017-04-09]\]. Conventionally, a variety of primer sets have been developed and used among laboratories for PCR analysis of Ig and TCR gene rearrangement \[[@b10-jptm-2017-04-09]-[@b13-jptm-2017-04-09]\]. In recent years, laboratory-developed PCR tests to detect Ig and TCR gene rearrangement are being gradually replaced by BIOMED-2 (or EuroClonality) assay, which is now commercially available as IdentiClone clonality assay (Invivoscribe Technologies Inc., San Diego, CA, USA) \[[@b3-jptm-2017-04-09],[@b6-jptm-2017-04-09],[@b14-jptm-2017-04-09]-[@b17-jptm-2017-04-09]\]. In brief, BIOMED-2 assays utilize 14 multiplex PCR tubes altogether, including three VH-JH, two DH-JH, two *IGK*, one *IGL*, three *TCRB*, two *TCRG*, and one *TCRD*, to detect B- and T-cell clonality ([Figs. 1](#f1-jptm-2017-04-09){ref-type="fig"}, [2](#f2-jptm-2017-04-09){ref-type="fig"}). The primer sets and design of multiplex PCR for each Ig and TCR gene rearrangement were previously described in detail \[[@b3-jptm-2017-04-09]\]. A set of BIOMED-2 assays can be selected and implemented in individual laboratory for clinical practice \[[@b6-jptm-2017-04-09]\].

Interpretation and reporting: PCR-based clonality assay
-------------------------------------------------------

Evaluation of PCR product for clonality test can be performed using gel-based assay or capillary electrophoresis (CE) by gene scanner ([Fig. 3](#f3-jptm-2017-04-09){ref-type="fig"}). Gel-based assays are represented by denaturing gradient gel electrophoresis (EP) and heteroduplex analysis followed by non-denaturing polyacrylamide gel electrophoresis (PAGE). While denaturing gel EP and CE analysis can discriminate PCR products based on the size difference, heteroduplex analysis with non-denaturing PAGE has a merit to discriminate PCR products on the basis of sequence differences as well as size differences \[[@b3-jptm-2017-04-09]\]. Thus, heteroduplex analysis can be considered to prevent false positive results.

In principal, monoclonal B- or T-cell population exhibits prominent unequivocal one or two clonal peak(s) and band(s) when analyzed by CE and gel-EP, respectively \[[@b3-jptm-2017-04-09],[@b6-jptm-2017-04-09],[@b15-jptm-2017-04-09],[@b17-jptm-2017-04-09]\]. A common definition of a prominent peak in CE is one that is greater than twice the size of the background polyclonal population \[[@b8-jptm-2017-04-09]\]. Meanwhile, commercial kits for BIOMED-2 assay defines a positive peak as one that is at least three times the amplitude of the third largest peak in the same polyclonal background distribution or the closest polyclonal background distribution to the product. Otherwise, commercial kit for BIOMED-2 assay of *TCRG* provides automated interpretation for the significance of a peak analyzed by CE through a mathematical algorithm. The presence of two predominant peaks rarely occurs, indicating biallelic rearrangements, usually at both TCR loci \[[@b17-jptm-2017-04-09]\]. Polyclonal B- or T-cell populations typically exhibit a Gaussian distribution when analyzed by CE and a smear when analyzed by gel-EP. However, in many clinical samples, a polyclonal background may not exhibit an expected distribution due to fewer number of reactive B or T cells, PCR efficiencies, and other factors \[[@b6-jptm-2017-04-09]\]. Moreover, it would be difficult to determine the presence of unequivocal clonality when weak peaks or bands are observed. Thus, interpretation of PCR-based clonality assay could be challenging.

Clonal peaks/bands observed in multiple multiplex-PCR reactions (i.e., tubes) and, moreover, reproducible in duplicate are highly convincing for the presence of monoclonal population. However, clear clonality would be detected in a single multiplex Ig/TCR PCR reaction (tube). The presence of an equivocal weak Ig/TCR band/peak within a polyclonal background can be regarded as low-level of clonality. Such equivocal products are often detected with either heteroduplex or Gene Scan. To avoid false-positivity of the clonality assay, duplicate test might be considered (see below), although not mandatory for the clonality test, particularly when using validated approved test \[[@b3-jptm-2017-04-09],[@b6-jptm-2017-04-09]\]. General guidelines for interpretation and reporting of Ig/TCR clonality test are summarized in [Table 1](#t1-jptm-2017-04-09){ref-type="table"}, on the condition that the test is appropriately validated.

Validation of test, quality assurance, and limitations and pitfalls
-------------------------------------------------------------------

Utility and accuracy of molecular clonality test are affected by both biological and technical factors. For appropriate interpretation of results and quality assurance of clonality test, pathologists must be well-acquainted with the limitations and pitfalls \[[@b3-jptm-2017-04-09]\]. Most importantly, pathologists and clinicians must understand that the results of clonality test should always be interpreted in the context of morphological, immunophenotypical, and clinical features of patients.

### Validation of test and quality assurance

Each assay should be performed along with positive, negative, and no template controls. If the controls do not yield the expected results, the assay is not valid and the samples should not be interpreted. To ensure the quality and quantity of DNA and the absence of inhibitors of PCR reactions, specimen control size ladder, which amplifies multiple genes ranging the size of PCR product for Ig and TCR genes, is essential. If no bands are seen or smaller sized products are amplified only, the assay or sample should be re-evaluated unless the test result of specimen is positive.

### Limited sensitivity and false-negative results

A sensitive PCR-based clonality test has detection limits of 1%--10%, depending on the applied techniques and the background of non-neoplastic B and T cells. In addition, false-negative results of PCR-based clonality test can be caused by improper primer annealing or difficulties in discrimination between monoclonal and polyclonal Ig/TCR gene rearrangements. Interpretation guideline of monoclonality and polyclonality is described above and in [Table 1](#t1-jptm-2017-04-09){ref-type="table"} and is also provided by manufacturer with commercial kit. However, this discrimination is occasionally not straightforward. In this case, analysis of multiple Ig and TCR genes and repeated examination might be helpful. Improper annealing of the PCR primers to the Ig and TCR genes can be mainly caused by two factors. First, family or consensus primers cannot precisely cover all different V, D, and J gene segments, particularly in Ig and TCR genes having many different gene segments. Second, mature B cells undergo somatic hypermutation in rearranged Ig genes and isotype class switching in germinal centers for affinity maturation of the Ig molecules. This physiologic phenomenon can hamper the proper annealing of PCR primers. Thus, mature B-cell lymphomas of germinal center or post-germinal center origin with somatically mutated Ig genes are more likely to show false-negative results \[[@b15-jptm-2017-04-09],[@b18-jptm-2017-04-09]\].

### Pseudoclonality and false-positive results

Pseudoclonality of a sensitive PCR assay refers to selective amplification of the Ig or TCR gene rearrangements from a few reactive B or T cells in the tissue samples, particularly in a small biopsy. Evaluating the reproducibility of clonal band/peak by performing duplicate or repeated PCR analyses will help to clarify whether the seemingly clonal PCR products are derived from different lymphocytes or not.6 On the other hand, PCR analyses can produce false-positive results, especially when discriminating the monoclonal, oligoclonal, or polyclonal populations solely based on the size of PCR products using techniques with low resolution. To avoid serious false-positive PCR results, discrimination of PCR products can be achieved via Gene Scanning, which has higher resolution than gel-based assay or via single-strand conformation polymorphism analysis, denaturing gradient gel EP and heteroduplex analysis \[[@b19-jptm-2017-04-09],[@b20-jptm-2017-04-09]\]. These latter techniques discriminate PCR products in terms of composition of nucleotides, in addition to the length of nucleotides, derived from junctional diversity during Ig/TCR gene rearrangements.

### Clonality is not equivalent to malignancy or lymphoma

Some clinically benign lymphoproliferative diseases (i.e., monoclonal gammopathy of unknown significance, lymphomatoid papulosis) can exhibit clonality. In addition, non-neoplastic lymphoproliferations including viral infection (i.e., Epstein-Barr virus, cytomegalovirus), bacterial infection (i.e., *Helicobacter pylori gastritis*), autoimmune diseases, and immunodeficiency status can harbor predominance of several antigen-specific subclones or reduced diversity of B- or T-cell repertoire, thus displaying oligoclonality or even monoclonality.

### Ig and TCR gene rearrangements are not markers for lineage

Crosslineage Ig/TCR gene rearrangements occur relatively frequently in immature T- or B-cell malignancies (i.e., acute lymphoblastic lymphomas), and even in acute myeloid leukemias \[[@b21-jptm-2017-04-09]-[@b24-jptm-2017-04-09]\]. Virtually all αβT cell lymphomas have *TCRG* gene rearrangements and many αβT cell lymphomas have *TCRB* gene rearrangements, implying that the detection of *TCRB* or *TCRG* rearrangements is not indicative of T cells of the αβ or γδβ T-cell lineage, respectively, either \[[@b5-jptm-2017-04-09],[@b8-jptm-2017-04-09],[@b21-jptm-2017-04-09],[@b25-jptm-2017-04-09],[@b26-jptm-2017-04-09]\]. Mature B- and T-cell lymphomas might rarely contain TCR and Ig gene rearrangements, respectively \[[@b21-jptm-2017-04-09],[@b24-jptm-2017-04-09]\]. Particularly, angioimmunoblastic T-cell lymphomas (AITL) frequently exhibit Ig gene rearrangements up to 20%--30% of cases \[[@b17-jptm-2017-04-09]\].

CHROMOSOME AND GENE TRANSLOCATIONS
==================================

Background and indications including changes in the 2016 revision of WHO classification
---------------------------------------------------------------------------------------

Structural alterations of chromosome and/or genes important for the diagnosis, prognostication and therapeutics in tumor include amplification, deletion and translocation (or rearrangement). B- and T-cell malignancies frequently undergo pathologic chromosome/gene rearrangement in addition to the physiologic rearrangement of Ig and TCR genes. Gene translocations in hematolymphoid malignancies result in the overexpression of oncogenes involving cell proliferation and apoptosis under the influence of Ig promoter or the production of fusion proteins having dysregulated expression or kinase activity. Gene translocations can be analyzed by multiple methods including conventional karyotyping, fluorescence *in situ* hybridization (FISH), Southern blotting, and reverse-transcription PCR. Otherwise, aberrant expression of proteins derived from gene translocation can be detected by immunohistochemistry \[[@b27-jptm-2017-04-09]\]. Common chromosome/gene translocations with diagnostic and clinical implications in mature B and T-cell lymphomas and the detection method commonly used for clinical practice are summarized in [Table 2](#t2-jptm-2017-04-09){ref-type="table"}.

Patients with DLBCL harboring *MYC* translocation (approximately in 5%--15% of DLBCL) or concurrent *MYC* and *BCL2* translocations (approximately in 5%--6% of DLBCL) had very poor prognosis \[[@b28-jptm-2017-04-09]-[@b31-jptm-2017-04-09]\]. Of note, the 2016 revision of WHO classification has newly introduced high-grade B-cell lymphomas with *MYC* and *BCL2* and/or *BCL6* translocations (other than follicular lymphoma and lymphoblastic lymphoma) as a category of "double-/triple-hit" lymphomas \[[@b32-jptm-2017-04-09]\]. These lymphomas morphologically resemble DLBCL or B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma which had been recognized in 2008 WHO classification \[[@b33-jptm-2017-04-09]\]. The patients with "double-/triple-hit" lymphomas show a very aggressive clinical course and poor prognosis despite high-intensity chemotherapy. However, a consensus has not yet been reached for the guidelines to test FISH for *MYC*, *BCL2*, and *BCL6* rearrangements in high-grade B-cell lymphoma. In contrast, MYC protein expression is observed in 30%--50% of DLBCLs and concomitant expression of MYC and BCL2 in 20%--35% of the cases; these "double-expressor lymphoma" cases are four to five times higher in incidence than those with MYC and BCL2 double-hit (i.e., translocation) \[[@b29-jptm-2017-04-09]-[@b31-jptm-2017-04-09],[@b34-jptm-2017-04-09]\]. Although a cut-off for MYC and BCL2 expression for double-expressor has varied among studies, a cutoff of 30% or 40% for MYC and a cutoff of 50% or 70% for BCL2 are usually used to define these cases \[[@b34-jptm-2017-04-09]\]. Several studies demonstrated that the double-expressor lymphomas have a worse outcome than other DLBCL, even irrespective of COO \[[@b31-jptm-2017-04-09]\]. Thus, the 2016 revision of WHO classification suggests that coexpression of MYC and BCL2 should be considered new prognostic indicator in DLBCL, not otherwise specified (NOS) \[[@b32-jptm-2017-04-09]\].

Method: FISH---procedures and probes
------------------------------------

Interphase FISH is now widely used to detect chromosome/gene translocations using FFPE tissue, fresh tissue, and cytologic samples. FISH is a process by which fluorochrome-labeled specific DNA probe hybridizes to a complementary location on a chromosome. FISH test includes selection of appropriate probe, pretreatment, hybridization and interpretation \[[@b35-jptm-2017-04-09],[@b36-jptm-2017-04-09]\]. When using validated probe, optimal pretreatment of tissue sections most affect the FISH test on FFPE tissue. Pretreatment refers to permeabilization of the cells to enable the probe to access the target DNA in the nucleus to hybridize. This procedure follows multiple steps including antigen retrieval procedure (i.e., citrate, EDTA), incubation with acid, detergent, and chaotropic agents (i.e., sodium thiocyanate \[NaSCN\]), and protease digestion, depending on the tissue condition. Hybridization procedures consist of co-denaturing target DNA and probe DNA at high temperature in the presence of formamide into single strands and incubating the slide to allow the probe DNA to attach to the target DNA \[[@b35-jptm-2017-04-09]\].

For detection of the common gene translocations in lymphoma, various probe sets and protocols for hybridization are now commercially available. FISH test for gene translocations are usually performed by two types of FISH probe \[[@b35-jptm-2017-04-09],[@b36-jptm-2017-04-09]\]. One is the dual-color "dual-fusion" probe (or two break points spanning probe), in which each translocation partner is identified by a probe of different color, usually red and green. The normal configuration is therefore two red signals and two green signals in each nucleus. When a translocation occurs between two genes, one of each signal is split and the different halves join together; these result in signal pattern of one red, one green, and two fused signals ([Fig. 4A](#f4-jptm-2017-04-09){ref-type="fig"}). This probe has a merit to assure the fusion partners exactly and is useful for the diagnosis of gene translocations involving specific genes as in follicular lymphoma, which mostly harbors *BCL2/IGH* fusion. However, it has limitations in applying to the gene translocations having multiple fusion partners and can show false positive signals due to nuclear or chromosome overlapping in tissue FISH. To detect a gene translocation that can involve multiple partners, a dual-color "break-apart" probe (or breakpoint flanking probe) can be more useful. With this type of probe, the normal configuration is two paired signals. If there is any translocation present involving this gene, the two colors will be split apart, resulting in one paired (normal) signal, one red, and one green ([Fig. 4B](#f4-jptm-2017-04-09){ref-type="fig"}). There could be a small gap or space between the two colors in some probe when the DNA is unwound. However, when the translocation occurs inter-chromosomally, the signals are usually separated with ample space and the rate of false-positivity is very low. Thus, this type of probe is useful for detecting gene translocation to make a diagnosis by integrating other pathological features. Selection of FISH probe depends on the disease entity and the purpose of the test.

Reporting
---------

In principle, FISH reporting follows a system for FISH nomenclature, the International System for Human Cytogenetic Nomenclature (ISCN) in both metaphase and interphase assay \[[@b27-jptm-2017-04-09],[@b35-jptm-2017-04-09],[@b37-jptm-2017-04-09]\]. If a 14;18 translocation resulting in fusion of the *IGH* and *BCL2* genes studied in interphase FISH using a dual-color, dualfusion probe set, the ISCN nomenclature would be written as follows: nuc ish (IGH × 3), (BCL2 × 3), (IGH con BCL2 × 2), indicating that each of the probes has been split apart and juxtaposed by the translocation. However, the system may seem confusing to pathologists not familiar with conventional cytogenetics, particularly those who are generally dealing with interphase FISH for solid tumors. FISH reporting may be modified according to the guideline provided by manufacturers of FISH probe and the purpose of the test in case of solid tumors. In principal, the report should also contain a statement as to the FISH results being normal or abnormal, and indicate the percentage of abnormal and normal cells. Specific names of the probes and the manufacturer and any specific limitations of the assay should be included in the report \[[@b36-jptm-2017-04-09]\]. Interpretation of the report on the diagnostic and prognostic significance of the FISH findings, with the clinicopathological findings incorporated, and suggestion of any further tests could be recommended.

Validation of the test and quality assurance
--------------------------------------------

When a new FISH test is implemented in the laboratory, extensive validation is required, including validation of the probe itself (probe validation) and validation of the procedures using the probe (analytical validation) (American College of Medical Genetics and Genomics, Standards and Guidelines for Clinical Genetic Laboratories, Section E: Clinical Cytogenetics, <http://www.acmg.net>) \[[@b36-jptm-2017-04-09]\]. Commercial probes, which are supplied by various manufacturers including Abbott (Vysis), Cambio, Cytocell, Dako, Kreatech, and Poseidon (Stretton), are generally easy to use and validated. However, because they can vary in terms of application, size (50 kb--1 Mb) and covered chromosome loci, users must read the datasheet and probe map very carefully and become familiar with the FISH pattern using the probe. Regarding the analytical validation in interphase FISH using FFPE tissue, normal reference ranges can be calculated by evaluating available tissues without the rearrangement being validated. To validate a FISH test, known normal and abnormal cases should be assessed to establish clearly defined scoring criteria for determining whether the assay is acceptable or not. For this, inter-laboratory cross-validation and participation in a proficiency testing program are recommended \[[@b36-jptm-2017-04-09]\].

CELL-OF-ORIGIN OF DIFFUSE LARGE B-CELL LYMPHOMA
===============================================

Background and indications including changes in the 2016 revision of WHO classification
---------------------------------------------------------------------------------------

Gene expression profiling (GEP) studies classified DLBCL into clinically and biologically distinct subsets reflecting COO as follows: germinal center B-cell (GCB)-like DLBCL expresses genes related to normal GCBs, and activated B-cell (ABC)-like DLBCL lacks genes expressed in GCBs but expresses genes related to BCR activated B cells arrested during plasmacytic differentiation. Unclassifiable cases cannot be put into either category. Patients with ABC DLBCL have a worse clinical outcome than do patients with GCB DLBCL when treated with R-CHOP regimen \[[@b38-jptm-2017-04-09]-[@b41-jptm-2017-04-09]\]. Because GEP is hard to implement in a routine clinical test, many efforts have been made to classify COO of DLBCL using immunohistochemistry (IHC) for several markers, despite issues on reproducibility and reliability of IHC algorithms \[[@b42-jptm-2017-04-09]-[@b45-jptm-2017-04-09]\]. The 2008 classification recognized GCB and ABC/non-GCB "molecular or immunohistochemical subgroups" of DLBCL based on GEP or IHC but considered these subclassification of DLBCL as optional \[[@b33-jptm-2017-04-09]\]. Subsequent studies have demonstrated that the differences in genetic alterations and activation of signaling pathways as well as prognosis between GCB and ABC/non-GCB DLBCLs may affect the potential therapeutic targets and personalized therapy of patients with DLBCL as described previously \[[@b46-jptm-2017-04-09]\]. Thus, the 2016 revision of WHO classification requires the identification of GCB versus ABC/nonGCB DLBCL using either GEP or IHC \[[@b32-jptm-2017-04-09]\].

Methodology
-----------

GEP using microarray, including Lymphochip microarray and Affymetrix microarray, robustly classified the GCB versus ABC DLBCL with prognostic significance \[[@b38-jptm-2017-04-09],[@b39-jptm-2017-04-09]\]. However, these assays need fresh tissue for a large amount of RNA of high-quality and have restrictions for clinical application. Thus, several immunohistochemical algorithms as surrogates have been developed, as represented by Hans and Choi algorithm ([Fig. 5](#f5-jptm-2017-04-09){ref-type="fig"}), which have shown reasonable correlations with GEP \[[@b42-jptm-2017-04-09],[@b43-jptm-2017-04-09]\]. However, in the following studies, the concordance rate between the immunohistochemically defined and GEP-defined subgroups has been variable and the IHC algorithm has some limitations in terms of accuracy, reproducibility and prognostic utility \[[@b44-jptm-2017-04-09],[@b45-jptm-2017-04-09]\].

Recently, a 20-gene gene expression assay using FFPE tissues and NanoString-based digital gene expression technology has been proposed for the determination of COO subgroups of DLBCL \[[@b47-jptm-2017-04-09]\]. This assay (Lymph2CX) identified GCB versus ABC/non-GCB subgroups by quantifying the RNA transcripts extracted from FFPE tissue and produced reproducible accuracy and prognostic value \[[@b48-jptm-2017-04-09]\]. Although these assays using nCounter system are not yet accessible to most laboratories, it may be a promising alternative to the IHC-based algorithms.

MOLECULAR TESTING USING NEXT-GENERATION SEQUENCING: FUTURE NEXT-GENERATION SEQUENCING PANEL FOR DIAGNOSTIC, PROGNOSTIC AND PREDICTIVE PURPOSE
=============================================================================================================================================

Background
----------

Assays for single gene detection have been replaced by NGS which allows for the simultaneous evaluation of many genes. Targeted sequencing for gene sets is appropriate for clinical purpose and can acquire information for diagnosis, prognostication, and therapeutic targets. Currently, Korea Food and Drug Administration (KFDA) allows two levels of NGS test panel. Level 1 is composed of less than 50 genes including *TP53* and *MYD88*. Level II is composed of less than 200 genes including *NOTCH1* and *NOTCH2*. Although there is no general guideline for which gene sets should be included in molecular test using NGS, it is recommended that genes for pathologic diagnosis and prognostication according to the WHO classification and genes with implications for standard clinical management and current clinical trial be included in the level I gene set. Level II gene set may include potential therapeutic targets which are identified in high throughput sequencing of malignant lymphoma, but have no available drug yet. Recommended list of genes is depicted in [Tables 3](#t3-jptm-2017-04-09){ref-type="table"} and [4](#t4-jptm-2017-04-09){ref-type="table"}.

Genes incorporated in the 2016 revision of WHO classification as a diagnostic marker
------------------------------------------------------------------------------------

Rearrangement of a specific gene is diagnostic for a certain type of malignant lymphoma. It includes BCL2 for follicular lymphoma, MYC for Burkitt lymphoma, simultaneous rearrangement of *MYC* with *BCL2* and/or *BCL6* for high grade B-cell lymphoma, and *CCND1*, *CCND2*, and *CCND3* for mantle cell lymphoma (MCL) \[[@b32-jptm-2017-04-09],[@b33-jptm-2017-04-09]\]. The 2016 revision of WHO classification incorporated a few additional genes in the diagnostic criteria \[[@b32-jptm-2017-04-09]\]. *BRAF* V600E mutations are found in almost all cases of hairy cell leukemia (HCL) but not in HCL-variant (HCL-v) or other small B-cell lymphoid neoplasms \[[@b49-jptm-2017-04-09]-[@b52-jptm-2017-04-09]\]. Mutations in *MAP2K1* which encodes MEK1 (which is downstream of BRAF) have been reported in almost half of HCL-v and in the majority of HCL that use IGHV4-34 and which, like HCL-v, lack *BRAF* V600E mutations \[[@b53-jptm-2017-04-09],[@b54-jptm-2017-04-09]\]. *MYD88* mutation is important in the differential diagnosis between nodal marginal zone lymphoma and lymphoplasmacytic lymphoma (LPL) \[[@b55-jptm-2017-04-09]-[@b58-jptm-2017-04-09]\]. Ninety percent of LPL or Waldenström macroglobulinemia have *MYD88* L265P mutations. This mutation is also found in a significant proportion of IgM, but not IgG or IgA, monoclonal gammopathy of undetermined significance cases, approximately 30% of non-GCB--type DLBCL, more than half of primary cutaneous DLBCL (leg type), and many DLBCL at immuneprivileged sites, but not in plasma cell myeloma, even of IgM type. *IG/IRF4* fusions are associated with a distinct subgroup of germinal center B-cell lymphomas composed of follicular lymphoma (FL) grade 3 or (centroblastic) DLBCL characterized by coexpression of MUM1 and BCL6 in the absence of PRDM1/BLIMP1, a specific gene expression profile, and a disease onset predominantly in childhood or young adulthood \[[@b59-jptm-2017-04-09]\]. A new provisional entity designated Burkitt-like lymphoma with 11q aberration has a chromosome 11q alteration characterized by proximal gains and telomeric losses, but without *MYC* rearrangement \[[@b60-jptm-2017-04-09],[@b61-jptm-2017-04-09]\].

Prognostic and predictive marker
--------------------------------

*TP53*, *NOTCH1*, *SF3B1*, and *BIRC3*, are of clinical interest because of their adverse prognostic implications in chronic lymphocytic leukemia (CLL) and also because some are potential direct or indirect therapeutic targets \[[@b62-jptm-2017-04-09],[@b63-jptm-2017-04-09]\]. *TP53* mutations are present in 10.6% of CLL, *ATM* mutations in 11.1%, *SF3B1* mutations in 12.6%, *NOTCH1* mutations in 21.8%, and *BIRC3* mutations in 4.2%. The ATM-p53 DNA damage response pathway plays a crucial role in chemoresistance in CLL, as indicated by the adverse prognostic impact of deletions of 17p (locus of *TP53*) and 11q (locus of *ATM*) detected by FISH analysis \[[@b64-jptm-2017-04-09]\]. BIRC3 is a negative regulator of noncanonical nuclear factor κB (NF-κB) signaling. BIRC3 disruption by inactivating mutations and/or gene deletions selectively affects fludarabine-refractory CLL cases \[[@b65-jptm-2017-04-09]\].

MCL is also characterized by having mutations affecting many different genes including *ATM* (40%--75%), *CCND1* (35%), and *TP53* (28%) \[[@b20-jptm-2017-04-09]\]. Mutations of *NOTCH1* and *NOTCH2* occur in less than 10% of cases and are identified in a subset of tumors with more adverse biological features including blastoid/pleomorphic morphology. NOTCH1 and NOTCH2 have prognostic impact and potential therapeutic importance in MCL \[[@b66-jptm-2017-04-09]\].

Mutations or copy number losses of *TP53* genes are independent unfavorable prognostic factors in different types of B-cell lymphomas \[[@b67-jptm-2017-04-09]\]. *CD58* gene encodes a molecule involved in T and natural killer (NK)-cell-mediated responses. In addition to *TP53*, mutations or copy number losses of *CD58* in DLBCL are independent unfavorable prognostic factors \[[@b68-jptm-2017-04-09]\]. Recurrent mutations of the exportin 1 gene (*XPO1*) have been observed in primary mediastinal B-cell lymphoma and Hodgkin lymphoma and they have prognostic implication \[[@b69-jptm-2017-04-09],[@b70-jptm-2017-04-09]\]. *TET2* is a tumor suppressor gene and frequently mutated in a variety of T or NK-cell lymphoma. *TET2* mutation is associated with advanced-stage disease, thrombocytopenia, high international prognostic index scores, and a shorter progression-free survival \[[@b71-jptm-2017-04-09],[@b72-jptm-2017-04-09]\].

Therapeutic targets
-------------------

Much has been learned about the mutational landscape of malignant lymphomas. Genes identified in NGS analysis are important in the development and progression of malignant lymphoma and are potential therapeutic targets although drugs are currently available for only some of these targets. Genes involved in BCR signaling which converges to mitogen-activated protein kinase pathway, NF-κB pathway, and phosphoinositide 3-kinase (PI3K) pathway are therapeutic targets of B-cell lymphomas ([Fig. 6](#f6-jptm-2017-04-09){ref-type="fig"}). These include CD79A/B, SYK, and SFK of BCR signaling pathway, BTK, PKCβ, CARD11, MALT1, BCL10, IKKα, IKKβ, and IKKγ of NF-κB pathway, and PI3K, AKT, and mammalian target of rapa*MYC*in of PI3K pathway \[[@b73-jptm-2017-04-09]\]. Most active clinical trials are targeting these genes. Mutations of chromatin regulator/modifier genes, such as *CREBBP*, *KMT2D* (MLL2), and *EZH2* are extremely common early events and may be potential therapeutic targets \[[@b74-jptm-2017-04-09]-[@b77-jptm-2017-04-09]\]. Chromosomal rearrangements of *DUSP22* and *TP63* were identified in 30% and 8% of anaplastic lymphoma kinase (ALK)--negative anaplastic large cell lymphoma (ALCL), respectively \[[@b78-jptm-2017-04-09]\]. ALCLs with *DUSP22* rearrangements show significant differences from other ALK-negative ALCLs, typically showing sheets of hallmark cells with doughnut cells and a few large pleomorphic cells \[[@b78-jptm-2017-04-09],[@b79-jptm-2017-04-09]\]. *DUSP22* functions as a tumor suppressor gene and potential therapeutic manipulation. T-cell lymphoma of follicular helper T-cell (TFH) phenotype including AITL is characterized by mutations of genes involved in the TCR signaling pathway including *RHOA* G17V mutation (70%), *CD28* mutation (11 %), *CTLA4-CD28* fusion (58 %), *PLCG1* (14.1%), *PI3K* elements (7%), *CTNNB1* (6%), and *GTF2I* (6%) ([Fig. 7](#f7-jptm-2017-04-09){ref-type="fig"}) \[[@b80-jptm-2017-04-09]-[@b85-jptm-2017-04-09]\]. Although mutations of *RHOA*, *CD28*, and *CTLA4-CD28* fusion themselves have no prognostic impact, targeting of TCR-related events may hold promise for the treatment of TFH-derived lymphomas. *SYK-ITK* fusion is detected in peripheral T-cell lymphoma (PTCL)-NOS, or AITL. The fusion kinase *ITK-SYK* mimics a TCR signal and drives oncogenesis in conditional mouse models of PTCL \[[@b86-jptm-2017-04-09],[@b87-jptm-2017-04-09]\]. *IDH2* mutation is frequently identified in AITL (19%--42%), but not in other types of T- or NK-cell lymphoma. These mutations alter IDH enzymatic function, resulting in the accumulation of D-2-hydroxyglutarate (D-2-HG) in cells and tissues. D-2-HG may act as an oncometabolite, driving tumor progression and affect hypoxia signaling (prolyl hydroxylases), histone methylation, and DNA methylation \[[@b88-jptm-2017-04-09],[@b89-jptm-2017-04-09]\]. Genes involved in JAK-STAT pathway are frequently mutated in extranodal NK/T-cell lymphoma, including STAT3 (most common), STAT5B, JAK3, and JAK1. Other commonly mutated genes include histone modification-related genes such as *BCOR* and *MLL2*, RNA helicase DDX3, and P53 \[[@b90-jptm-2017-04-09]-[@b92-jptm-2017-04-09]\]. All these genes are important in the progression of NK/T-cell lymphoma and may be potential therapeutic targets. In addition to these genes, there are genes with inhibitors available, which are being tried in clinical trials.

Samples for targeted sequencing
-------------------------------

FFPE sample is available for targeted sequencing. Single nucleotide variants and copy number alteration can be detected using DNA extracted from FFPE tissue and the translocation can be identified by RNA sequencing using FFPE samples. In general, lymphoma is often highly cellular; therefore, DNA extracted from FFPE sample is sufficient to obtain sequencing data, although there is a variation in the minimum requirement of DNA amount according to the NGS platform. Before starting the test, development of optimum operating procedure in each laboratory is mandatory.

CONCLUSION
==========

Molecular diagnostics for B- and T-cell clonality test and cytogenetic test for malignant lymphoma have been much improved and introduced in routine clinical practice. In addition, determination of COO in DLBCL and NGS-based tests for genetic alterations in malignant lymphomas will open a pathway toward personalized medicine and targeted therapy in the near future.
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![Structure of *IGH* genes and the BIOMED-2 multiplex *IGH* gene polymerase chain reaction assay.](jptm-2017-04-09f1){#f1-jptm-2017-04-09}

![Structure of *TCRG* genes and the BIOMED-2 multiplex *TCRG* gene polymerase chain reaction assay.](jptm-2017-04-09f2){#f2-jptm-2017-04-09}

![Representative results and interpretation of BIOMED-2 multiplex IGH PCR analyzed by gene scanning. Clonal *IGH* gene rearrangement was detected in case (A), but not in case (B).](jptm-2017-04-09f3){#f3-jptm-2017-04-09}

![Fluorescence *in situ* hybridization analysis to detect gene translocations using dual color, dual fusion probe (arrow, fused IGH and BCL2 genes) (A) and dual color, break apart probe (arrows, splitted *MALT1* genes) (B). MALT, mucosa-associated lymphoid tissue.](jptm-2017-04-09f4){#f4-jptm-2017-04-09}

![Representative immunohistochemical algorithms for the subgrouping of diffuse large B-cell lymphoma \[[@b42-jptm-2017-04-09], [@b43-jptm-2017-04-09]\]. GCB, germinal center B-cell.](jptm-2017-04-09f5){#f5-jptm-2017-04-09}

![Genes involved in B-cell receptor signaling which converges to mitogen-activated protein (MAP) kinase pathway, nuclear factor κB (NF-κB) pathway, and phosphoinositide 3-kinase (PI3K) pathway are the therapeutic targets of B-cell lymphomas. MAPK, mitogen-activated protein kinase; MAPKK, mitogen-activated protein kinase kinase; MAPKKK, mitogen-activated protein kinase kinase kinase; mTOR, mammalian target of rapamycin. Modified from Young *et al*. Semin Hematol 2015;52:77-85, with permission of Elsevier \[[@b73-jptm-2017-04-09]\].](jptm-2017-04-09f6){#f6-jptm-2017-04-09}

![T-cell receptor signaling-related genes in nodal lymphomas of follicular helper T-cell phenotype are therapeutic targets. PI3K, phosphoinositide 3-kinase; NF-κB, nuclear factor κB; MAPK, mitogen-activated protein kinase. Modified from Vallois *et al*. Blood 2016;128:1490- 502, with permission of American Society of Hematology \[[@b84-jptm-2017-04-09]\].](jptm-2017-04-09f7){#f7-jptm-2017-04-09}

###### 

EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing

  Type of profile per tube (in duplicate)                                                                                                                                   Technical description                                                      Molecular interpretation/conclusion
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------- ------------------------------------------------
  No peaks/bands (but: poor DNA quality)                                                                                                                                    No (specific) product, poor DNA quality                                    Not evaluable, due to poor DNA quality
  No peaks/bands (without background)                                                                                                                                       No (specific) product                                                      No rearrangement in Ig/TCR targets detected
  One or two reproducible clonal peaks/bands^[a](#tfn1-jptm-2017-04-09){ref-type="table-fn"}^                                                                               Clonal^[b](#tfn2-jptm-2017-04-09){ref-type="table-fn"}^                    Clonality detected
  One or two non-reproducible (clear) peaks/bands^[a](#tfn1-jptm-2017-04-09){ref-type="table-fn"}^                                                                          Pseudoclonal                                                               No clonality detected, suggestive
  Multiple (n \> 3) non-reproducible peaks/bands^[a](#tfn1-jptm-2017-04-09){ref-type="table-fn"}^                                                                           Pseudoclonal                                                               of low template amount
  Multiple (n \> 3) reproducible peaks/band^[a](#tfn1-jptm-2017-04-09){ref-type="table-fn"},[c](#tfn3-jptm-2017-04-09){ref-type="table-fn"}^                                Multiple products                                                          Oligoclonality/multiple clones detected
  Gaussian curve/smear^[d](#tfn4-jptm-2017-04-09){ref-type="table-fn"}^ (with or without minor reproducible peaks/bands^[a](#tfn1-jptm-2017-04-09){ref-type="table-fn"}^)   Polyclonal (not clonal^[d](#tfn4-jptm-2017-04-09){ref-type="table-fn"}^)   Polyclonality detected (no clonality detected)
  Polyclonality detected plus minor clone of unknown significance^[e](#tfn5-jptm-2017-04-09){ref-type="table-fn"}^                                                                                                                                     
  Pattern that cannot be categorized as one of the above                                                                                                                    Not evaluable^[f](#tfn6-jptm-2017-04-09){ref-type="table-fn"}^             Not evaluable

Reprinted by permission from Macmillan Publishers Ltd: \[Leukemia\] Langerak *et al*. 2012;26:2159-71, \[[@b6-jptm-2017-04-09]\] copyright (2012).

TCR, T-cell receptor.

In heteroduplex analysis the number of bands does not necessarily reflect the number of different polymerase chain reaction products, as additional heteroduplexes can be formed between products;

Clonal peaks/bands are not necessarily seen for every Ig/TCR target analyzed to reach the molecular conclusion 'clonality detected';

For *IGK* and TCRB loci up to four clonal products may be compatible with one clone;

In heteroduplex analysis a polyclonal smear may not always be smooth or clear, despite specific product in gel; hence this is scored as 'not clonal';

For those cases in which minor reproducible peaks/bands are detected in the polyclonal background;

In \< 5% of polymerase chain reaction results the description per tube cannot be made.

###### 

Common chromosome/gene translocations having diagnostic and clinical implications in mature B- and T-cell lymphoma

  Entity                                                                                                                                                         Chromosome/Gene translocation           Frequency          Detection method   Implication
  -------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------- ------------------ ------------------ ---------------------------------------------------------------
  Mantle cell lymphoma                                                                                                                                           t(11;14)(q13:q32), *CCND1* and *IGH*    \> 90%             IHC, FISH          Diagnostic
  Follicular lymphoma                                                                                                                                            t(14;18)(q32:q21), *BCL2* and *IGH*     Grade 1, 2: 90%    IHC, FISH          Diagnostic
  t(2;18)(p12:q21), *BCL2* and *IGK*                                                                                                                             Grade 3a, 3b: \< 30%                                                          
  Burkitt lymphoma                                                                                                                                               t(8;14)(q24:q32), *MYC* and *IGH*       \> 95%             FISH               Diagnostic
  t(2;8)(p12;q24), *MYC* and *IGK*                                                                                                                                                                                                             
  t(8;22)(q24;q11), *MYC* and *IGL*                                                                                                                                                                                                            
  Diffuse large B-cell lymphoma                                                                                                                                  t(8)(q24), *MYC*                        \~10%              FISH               Prognostic (poor)
  High-grade B-cell lymphoma with *MYC* and *BCL2* and/or *BCL6* rearrangements (double-/triple-hit lymphoma)^[a](#tfn7-jptm-2017-04-09){ref-type="table-fn"}^   t(8)(q24), *MYC*                                           FISH               Diagnostic
  t(14;18)(q32:q21), *BCL2* and *IGH*                                                                                                                            Prognostic (poor)                                                             
  t(3)(q27), *BCL6*                                                                                                                                                                                                                            
  MALT lymphoma                                                                                                                                                  t(11;18)(q21;q21), *API2* and *MALTI*   5%-20% (stomach)   FISH               Therapeutic (resistance to *Helicobacter pyroii* eradication)
  30%-50% (lung)                                                                                                                                                 RT-PCR                                                                        
  Anaplastic large cell lymphoma, ALK-positive                                                                                                                   t(2;5)(p23;q35), *NPM* and *ALK*        t(2;5) 85%         IHC, FISH          Diagnostic
  Variants involving 2p23, *ALK*                                                                                                                                 Variants 15%                            Prognostic                            

IHC, immunohistochemistry; FISH, fluorescence *in situ* hybridization; MALT, mucosa-associated lymphoid tissue; RT-PCR, reverse transcription polymerase chain reaction; ALK, anaplastic lymphoma kinase.

Included in the 2016 Revision of World Health Organization classification.

###### 

Level I gene list in NGS panel

  Genes                    Purpose of test        
  ------------------------ ----------------- ---- ----
  11q gain/loss            O                 \-   \-
  1P36 deletion            O                 \-   \-
  *AKT*                    \-                \-   O
  *ALK*                    \-                \-   O
  *BCL2* translocation     O                 \-   O
  *BCL6* translocation     O                 \-   O
  *BCOR*                   \-                \-   O
  *BIRC3*                  \-                O    \-
  *BRAF* V600E             O                 \-   \-
  *BTK*                    \-                \-   O
  Calcineurin              \-                \-   O
  *CARD11*                 \-                \-   O
  *CCND1* rearrangement    O                 \-   \-
  *CD28*                   \-                \-   O
  *CD58*                   \-                O    \-
  *CD79A*                  \-                \-   O
  *CD79B*                  \-                \-   O
  *CDK4*                   \-                \-   O
  *CDK6*                   \-                \-   O
  *CHEK1*                  \-                \-   O
  *CTLA4*                  \-                \-   O
  *CXCR4*                  \-                O    O
  *DDX3X*                  \-                O    \-
  *DUSP22* rearrangement   \-                O    \-
  *EZH2*                   \-                \-   O
  *FYN*                    \-                \-   O
  *GATA3*                  \-                O    \-
  *IDH2*                   \-                O    O
  *IRAK1*                  \-                \-   O
  *IRAK4*                  \-                \-   O
  *IRF4*                   O                 \-   \-
  *JAK1*                   \-                \-   O
  *JAK2*                   \-                \-   O
  *MAP2K1*                 \-                \-   \-
  *MAPK*                   \-                \-   O
  *MLL2*                   \-                \-   O
  *MTOR*                   \-                \-   O
  *MYC* rearrangement      O                 \-   O
  *MYD88*                  O                 \-   O
  *PI3K*                   \-                \-   O
  *PI3KCD*                 \-                \-   O
  *PKCbeta*                \-                \-   O
  *RHOA*                   O                 \-   O
  *STAT3*                  \-                \-   O
  *SYK*                    \-                \-   O
  *TBL1XR1*                \-                \-   O
  *TP53*                   \-                O    \-
  *TP63* rearrangement     \-                O    \-
  *VAV1*                   \-                \-   O
  *XPO1*                   \-                O    \-

NGS, next-generation sequencing.

###### 

Level II gene list in NGS panel

  ----------------- -------------------- ------------- ----------------- ----------------
  *ACTB*            *ANKRD11*            *APC*         *AR1D1A*          *ATM*
  *AURKA*           *AURKB*              *B2M*         *BAP1*            *BCL10*
  *BCL11B*          *BCL2L2*             *BCL7A*       *BCORL1*          *BRCA1*
  *BRCA2*           *BTG1*               *CCND2*       *CCND3*           *CCNE1*
  *CCR4*            *CCT6B*              *CD22*        *CD274 (PDL1)*    *CDK12*
  *CDK8*            *CDKN1B*             *CDKN2A*      *CDKN2B*          *CDKN2C*
  *CHEK2*           *CIITA*              *DNMT3A*      *DUSP9*           *EGFR*
  *EP300*           *ERG-1*              *ERK*         *ETS1*            *ETm1*
  *Em*              *ETm6*               *FAK*         *FAS (TNFRSF6)*   *FGFR1, 3*
  *FOXO1*           *FOXO3*              *FOXP1*       *GNA13*           *HDAC1*
  *HDAC4*           *HDAC7*              *HIST1H1C*    *HIST1H1D*        *HIST1H1E*
  *HIST1H2AC*       *HIST1H2AG*          *HIST1H2AL*   *HIST1H2AM*       *HIST1H2BC*
  *HIST1H2BJ*       *HIST1H2BK*          *HIST1H2BO*   *HIST1H3B*        *HRAS*
  *ID3*             *IGH*                *IGK*         *IGL*             *IKBKE*
  *IKKapha*         *IKKbeta*            *IKKgamma*    *IL7R*            *IRF1*
  *IRF8*            *JAK3*               *JUN*         *KLHL6*           *KMT2A (MLL)*
  *KMT2B (MLL2)*    *KMT2C (MLL3)*       *KRAS*        *LEF1*            *LILRB1*
  *LYN*             *MAF*                *MALT1*       *MAP2K2*          *MAP2K4*
  *MAP3K1*          *MAP3K14*            *MAP3K6*      *MAP3K7*          *MAPK1*
  *MCL1*            *MDM2*               *MDM4*        *MED12*           *MEF2B*
  *MEF2C*           *MET*                *MUC2*        *MYCL (MYCL1)*    *MYCN*
  *NF1*             *NF2*                *NFAT*        *NFKBIA*          *NORE1*
  *NOTCH 2*         *NOTCH1*             *NPM1*        *NRAS*            *NTRK2*
  *NTRK3*           *P2RY8*              *PAX5*        *PCLO*            *PDCD1 (PD-1)*
  *CD274 (PD-L1)*   *PDCD1LG2 (PD-L2)*   *PDGFRA*      *PDGFRB*          *PIK3CA*
  *PIK3CG*          *PIK3R1*             *PIK3R2*      *PIM1*            *PLCgamma 1*
  *PLCgamma2*       *POU2F2*             *PRDM1*       *PRKD2*           *PTEN*
  *PTPN1*           *RAF*                *RASSF1*      *RB1*             *RET*
  *RHOT2*           *RUNX1*              *SETBP1*      *SETD2*           *SF3B1*
  *SF3B1*           *SFK*                *SGK1*        *SMAD2*           *SMAD4*
  *SMARCA1*         *SMARCA4*            *SMARCAL1*    *SMARCB1*         *SMARCD1*
  *SOCS1*           *SOCS2*              *SOCS3*       *SOX10*           *SOX2*
  *STAT1*           *STAT2*              *STAT4*       *STAT5A*          *STAT5B*
  *STAT6*           *TCF3*               *TCL1A*       *TET1*            *TET2*
  *TET3*            *TLL2*               *TNFAIP3*     *TNFRSF11A*       *TNFRSF14*
  *TNFRSF17*        *TRAF2*              *TRAF3*       *TRAF5*           *TSC1*
  *TSC2*            *TYK2*               *WIF1*        *WT1*             *XBP1*
  *CTNNB1*          *GSK3B*              *PDK1*                          
  ----------------- -------------------- ------------- ----------------- ----------------

NGS, next-generation sequencing.
